This HTML5 document contains 99 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00790/identifier/chemspider/
n29http://linked.opendata.cz/resource/AHFS/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00790/identifier/chebi/
n9http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n7http://linked.opendata.cz/resource/drugbank/company/
n10http://linked.opendata.cz/resource/drugbank/dosage/
n31http://linked.opendata.cz/resource/drugbank/mixture/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00790/identifier/wikipedia/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00790/identifier/pharmgkb/
n30http://bio2rdf.org/drugbank:
n19http://linked.opendata.cz/resource/drugbank/drug/DB00790/identifier/kegg-compound/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00790/identifier/pubchem-compound/
admshttp://www.w3.org/ns/adms#
n28http://www.rxlist.com/cgi/generic/
n12http://linked.opendata.cz/resource/drugbank/patent/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00790/identifier/kegg-drug/
n27http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00790/identifier/pubchem-substance/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00790/identifier/drugbank/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n11http://linked.opendata.cz/resource/drugbank/medicinal-product/
n8http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n25http://www.drugs.com/cdi/
n6http://linked.opendata.cz/resource/drugbank/property/
n32http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00790/identifier/national-drug-code-directory/
xsdhhttp://www.w3.org/2001/XMLSchema#
n5http://linked.opendata.cz/resource/atc/
n4http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00790
rdf:type
n3:Drug
n3:description
Perindopril is a nonsulfhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly metabolized in the liver to perindoprilat, its active metabolite, following oral administration. Perindoprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Perindopril may be used to treat mild to moderate essential hypertension, mild to moderate congestive heart failure, and to reduce the cardiovascular risk of individuals with hypertension or post-myocardial infarction and stable coronary disease.
n3:dosage
n10:271B6365-363D-11E5-9242-09173F13E4C5 n10:271B6366-363D-11E5-9242-09173F13E4C5 n10:271B6367-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Hurst M, Jarvis B: Perindopril: an updated review of its use in hypertension. Drugs. 2001;61(6):867-96. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11398915 # Jastrzebskal M, Widecka K, Naruszewicz M, Ciechanowicz A, Janczak-Bazan A, Foltynska A, Goracy I, Chetstowski K, Wesotowska T: Effects of perindopril treatment on hemostatic function in patients with essential hypertension in relation to angiotensin converting enzyme (ACE) and plasminogen activator inhibitor-1 (PAI-1) gene polymorphisms. Nutr Metab Cardiovasc Dis. 2004 Oct;14(5):259-69. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15673060 # Parker E, Aarons L, Rowland M, Resplandy G: The pharmacokinetics of perindoprilat in normal volunteers and patients: influence of age and disease state. Eur J Pharm Sci. 2005 Sep;26(1):104-13. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15982858 # Simpson D, Noble S, Goa KL: Perindopril: in congestive heart failure. Drugs. 2002;62(9):1367-77; discussion 1378-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12076191 # Yasumatsu R, Nakashima T, Masuda M, Ito A, Kuratomi Y, Nakagawa T, Komune S: Effects of the angiotensin-I converting enzyme inhibitor perindopril on tumor growth and angiogenesis in head and neck squamous cell carcinoma cells. J Cancer Res Clin Oncol. 2004 Oct;130(10):567-73. Epub 2004 Jul 27. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15449186 # Yoshiji H, Kuriyama S, Kawata M, Yoshii J, Ikenaka Y, Noguchi R, Nakatani T, Tsujinoue H, Fukui H: The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor. Clin Cancer Res. 2001 Apr;7(4):1073-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11309359
n3:group
approved
n3:halfLife
Perindopril, 1.2 hours; Peridoprilat, 30-120 hours. The long half life of peridoprilat is due to its slow dissociation from ACE binding sites.
n3:indication
For the treatment of mild to moderate essential hypertension, mild to moderate congestive heart failure, and to reduce the cardiovascular risk of individuals with hypertension or post-myocardial infarction and stable coronary disease.
n3:manufacturer
n7:271B6357-363D-11E5-9242-09173F13E4C5 n7:271B6358-363D-11E5-9242-09173F13E4C5 n7:271B635B-363D-11E5-9242-09173F13E4C5 n7:271B6359-363D-11E5-9242-09173F13E4C5 n7:271B635A-363D-11E5-9242-09173F13E4C5
owl:sameAs
n27:DB00790 n30:DB00790
dcterms:title
Perindopril
adms:identifier
n14:8024 n15:96956 n16:107807 n17:46508767 n18:0032-1101-01 n19:C07706 n20:D03753 n21:DB00790 n22:PA450877 n23:Perindopril
n3:mechanismOfAction
There are two isoforms of ACE: the somatic isoform, which exists as a glycoprotein comprised of a single polypeptide chain of 1277; and the testicular isoform, which has a lower molecular mass and is thought to play a role in sperm maturation and binding of sperm to the oviduct epithelium. Somatic ACE has two functionally active domains, N and C, which arise from tandem gene duplication. Although the two domains have high sequence similarity, they play distinct physiological roles. The C-domain is predominantly involved in blood pressure regulation while the N-domain plays a role in hematopoietic stem cell differentiation and proliferation. ACE inhibitors bind to and inhibit the activity of both domains, but have much greater affinity for and inhibitory activity against the C-domain. Perindoprilat, the active metabolite of perindopril, competes with ATI for binding to ACE and inhibits and enzymatic proteolysis of ATI to ATII. Decreasing ATII levels in the body decreases blood pressure by inhibiting the pressor effects of ATII as described in the Pharmacology section above. Perindopril also causes an increase in plasma renin activity likely due to a loss of feedback inhibition mediated by ATII on the release of renin and/or stimulation of reflex mechanisms via baroreceptors.
n3:packager
n7:271B6353-363D-11E5-9242-09173F13E4C5 n7:271B6354-363D-11E5-9242-09173F13E4C5 n7:271B6351-363D-11E5-9242-09173F13E4C5 n7:271B6352-363D-11E5-9242-09173F13E4C5 n7:271B6355-363D-11E5-9242-09173F13E4C5 n7:271B6356-363D-11E5-9242-09173F13E4C5 n7:271B634F-363D-11E5-9242-09173F13E4C5 n7:271B6350-363D-11E5-9242-09173F13E4C5
n3:patent
n12:1341196 n12:5162362 n12:2473205
n3:routeOfElimination
Perindopril is extensively metabolized following oral administration, with only 4 to 12% of the dose recovered unchanged in the urine.
n3:synonym
(2S,3AS,7as)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxopentan-2-yl]amino}propanoyl]octahydro-1H-indole-2-carboxylic acid Perindopril Erbumine Perindoprilum
n3:toxicity
The most likely symptom of overdose is severe hypotension. The most common adverse effects observed in controlled clinical trials include cough, digestive symptoms, fatigue, headache, and dizziness.
n4:hasAHFSCode
n29:24-32-04
n3:foodInteraction
Take without regard to meals. Perindopril may decrease the excretion of potassium. Salt substitutes containing potassium may increase the risk of hyperkalemia. Herbs that may attenuate the antihypertensive effect of perindopril include: bayberry, blue cohash, cayenne, ephedra, ginger, ginseng (American), kola and licorice. High salt intake may attenuate the antihypertensive effect of perindopril.
n3:mixture
n31:271B634D-363D-11E5-9242-09173F13E4C5 n31:271B634E-363D-11E5-9242-09173F13E4C5
n3:proteinBinding
Perindoprilat, 10-20% bound to plasma proteins
n3:synthesisReference
Michel Vincent, Jean Baliarda, Bernard Marchand, Georges Remond, "Process for the industrial synthesis of perindopril." U.S. Patent US4914214, issued April 03, 1990.
n8:hasConcept
n9:M0129811
foaf:page
n25:perindopril.html n28:aceon.htm n32:ace1543.shtml
n3:IUPAC-Name
n6:271B636C-363D-11E5-9242-09173F13E4C5
n3:InChI
n6:271B6372-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n6:271B6371-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n6:271B636E-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n6:271B636F-363D-11E5-9242-09173F13E4C5
n3:SMILES
n6:271B6370-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n6:271B636A-363D-11E5-9242-09173F13E4C5
n3:logP
n6:271B6382-363D-11E5-9242-09173F13E4C5 n6:271B636B-363D-11E5-9242-09173F13E4C5 n6:271B6368-363D-11E5-9242-09173F13E4C5
n3:logS
n6:271B6369-363D-11E5-9242-09173F13E4C5
n4:hasATCCode
n5:C09AA04
n3:H-Bond-Acceptor-Count
n6:271B6378-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n6:271B6379-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n6:271B6373-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n6:271B6374-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n6:271B6376-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n6:271B6375-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n6:271B6377-363D-11E5-9242-09173F13E4C5
n3:absorption
Rapidly absorbed with peak plasma concentrations occurring approximately 1 hour after oral administration. Bioavailability is 65-75%. Following absorption, perindopril is hydrolyzed to perindoprilat, which has an average bioavailability of 20%. The rate and extent of absorption is unaffected by food. However, food decreases the extent of biotransformation to peridoprilat and reduces its bioavailability by 35%.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
107133-36-8
n3:category
n3:clearance
* 219 - 362 mL/min [oral administration]
n3:containedIn
n11:271B635F-363D-11E5-9242-09173F13E4C5 n11:271B6360-363D-11E5-9242-09173F13E4C5 n11:271B635D-363D-11E5-9242-09173F13E4C5 n11:271B635E-363D-11E5-9242-09173F13E4C5 n11:271B635C-363D-11E5-9242-09173F13E4C5 n11:271B6363-363D-11E5-9242-09173F13E4C5 n11:271B6364-363D-11E5-9242-09173F13E4C5 n11:271B6361-363D-11E5-9242-09173F13E4C5 n11:271B6362-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n6:271B637E-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n6:271B6380-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n6:271B6381-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n6:271B637D-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n6:271B637C-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n6:271B637F-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n6:271B636D-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n6:271B637A-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n6:271B637B-363D-11E5-9242-09173F13E4C5